{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T19:36:24Z","timestamp":1770147384740,"version":"3.49.0"},"reference-count":40,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23001","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T22:14:14Z","timestamp":1682633654000},"page":"99-107","source":"Crossref","is-referenced-by-count":7,"title":["Long-term effectiveness and safety of high dose chemotherapy followed                    by autologous stem cell transplantation in daily practice in patients with                    diffuse large B-cell lymphoma"],"prefix":"10.3960","volume":"63","author":[{"given":"Takahiro","family":"Haeno","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Minamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kakutani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Serizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Hirase","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ashida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University                            Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Teras                            LR,                                DeSantis                            CE,                                Cerhan                            JR                    <i>et al.<\/i> 2016 US lymphoid malignancy statistics by World Health                    Organization subtypes. CA Cancer J Clin. 2016; 66: 443-459.","DOI":"10.3322\/caac.21357"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Coiffier                            B,                                Lepage                            E,                                Bri\u00e8re                            J                    <i>et al.<\/i> CHOP chemotherapy plus rituximab compared with CHOP                    alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.                    2002; 346: 235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Vitolo                            U,                                Trn\u011bn\u00fd                            M,                                Belada                            D                    <i>et al.<\/i> Obinutuzumab or Rituximab Plus Cyclophosphamide,                    Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large                    B-Cell Lymphoma. J Clin Oncol. 2017; 35: 3529-3537.","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Philip                            T,                                Guglielmi                            C,                                Hagenbeek                            A                    <i>et al.<\/i> Autologous bone marrow transplantation as compared with                    salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s                    lymphoma. N Engl J Med. 1995; 333: 1540-1545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Gisselbrecht                            C, Van                                Den Neste                            E. How I manage                    patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol.                    2018; 182: 633-643.","DOI":"10.1111\/bjh.15412"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Gisselbrecht                            C,                                Glass                            B,                                Mounier                            N                    <i>et al.<\/i> Salvage regimens with autologous transplantation for                    relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28:                    4184-4190.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Crump                            M,                                Kuruvilla                            J,                                Couban                            S                    <i>et al.<\/i> Randomized comparison of gemcitabine, dexamethasone, and                    cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before                    autologous stem-cell transplantation for relapsed and refractory aggressive                    lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014; 32: 3490-3496.","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Lekakis                            LJ,                                Moskowitz                            CH. The Role of                    Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell                    Lymphoma in the Era of CAR-T Cell Therapy. HemaSphere. 2019; 3:                        e295.","DOI":"10.1097\/HS9.0000000000000295"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Hamadani                            M,                                Hari                            PN,                                Zhang                            Y                    <i>et al.<\/i> Early failure of frontline rituximab-containing                    chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility                    of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant.                    2014; 20: 1729-1736.","DOI":"10.1016\/j.bbmt.2014.06.036"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bachanova                            V,                                Perales                            MA,                                Abramson                            JS. Modern                    management of relapsed and refractory aggressive B-cell lymphoma: A perspective                    on the current treatment landscape and patient selection for CAR T-cell therapy.                    Blood Rev. 2020; 40: 100640.","DOI":"10.1016\/j.blre.2019.100640"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Van                                Den Neste                            E,                                Schmitz                            N,                                Mounier                            N                    <i>et al.<\/i> Outcome of patients with relapsed diffuse large B-cell                    lymphoma who fail second-line salvage regimens in the International CORAL study.                    Bone Marrow Transplant. 2016; 51: 51-57.","DOI":"10.1038\/bmt.2015.213"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Campo                            E,                                Swerdlow                            SH,                                Harris                            NL                    <i>et al.<\/i> The 2008 WHO classification of lymphoid neoplasms and                    beyond: evolving concepts and practical applications. Blood. 2011; 117:                    5019-5032.","DOI":"10.1182\/blood-2011-01-293050"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hans                            CP,                                Weisenburger                            DD,                                Greiner                            TC                    <i>et al.<\/i> Confirmation of the molecular classification of diffuse                    large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood.                    2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cheson                            BD,                                Fisher                            RI,                                Barrington                            SF                    <i>et al.<\/i> Recommendations for initial evaluation, staging, and                    response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano                    classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Sehn                            LH,                                Berry                            B,                                Chhanabhai                            M                    <i>et al.<\/i> The revised International Prognostic Index (R-IPI) is a                    better predictor of outcome than the standard IPI for patients with diffuse                    large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109:                    1857-1861.","DOI":"10.1182\/blood-2006-08-038257"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 . A predictive model for                    aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329:                    987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Stiff                            PJ,                                Unger                            JM,                                Cook                            JR                    <i>et al.<\/i> Autologous transplantation as consolidation for                    aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 2013; 369:                    1681-1690.","DOI":"10.1056\/NEJMoa1301077"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Schmitz                            N,                                Nickelsen                            M,                                Ziepert                            M                    <i>et al.<\/i> Conventional chemotherapy (CHOEP-14) with rituximab or                    high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients                    with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial                    (DSHNHL 2002-1). Lancet Oncol. 2012; 13: 1250-1259.","DOI":"10.1016\/S1470-2045(12)70481-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Cortelazzo                            S,                                Tarella                            C,                                Gianni                            AM                    <i>et al.<\/i> Randomized Trial Comparing R-CHOP Versus High-Dose                    Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell                    Lymphomas. J Clin Oncol. 2016; 34: 4015-4022.","DOI":"10.1200\/JCO.2016.67.2980"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Chiappella                            A,                                Martelli                            M,                                Angelucci                            E                    <i>et al.<\/i> Rituximab-dose-dense chemotherapy with or without                    high-dose chemotherapy plus autologous stem-cell transplantation in high-risk                    diffuse large B-cell lymphoma (DLCL04): final results of a multicentre,                    open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017; 18:                    1076-1088.","DOI":"10.1016\/S1470-2045(17)30444-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gisselbrecht                            C,                                Schmitz                            N,                                Mounier                            N                    <i>et al.<\/i> Rituximab maintenance therapy after autologous stem-cell                    transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma:                    final analysis of the collaborative trial in relapsed aggressive lymphoma. J                    Clin Oncol. 2012; 30: 4462-4469.","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Filmont                            JE,                                Gisselbrecht                            C,                                Cuenca                            X                    <i>et al.<\/i> The impact of pre- and post-transplantation positron                    emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma                    patients undergoing autologous stem cell transplantation. Cancer. 2007; 110:                    1361-1369.","DOI":"10.1002\/cncr.22911"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Sauter                            CS,                                Matasar                            MJ,                                Meikle                            J                    <i>et al.<\/i> Prognostic value of FDG-PET prior to autologous stem                    cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.                    Blood. 2015; 125: 2579-2581.","DOI":"10.1182\/blood-2014-10-606939"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Armand                            P,                                Welch                            S,                                Kim                            HT                    <i>et al.<\/i> Prognostic factors for patients with diffuse large B                    cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell                    transplantation in the positron emission tomography era. Br J Haematol. 2013;                    160: 608-617.","DOI":"10.1111\/bjh.12176"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Terasawa                            T,                                Dahabreh                            IJ,                                Nihashi                            T.                    Fluorine-18-fluorodeoxyglucose positron emission tomography in response                    assessment before high-dose chemotherapy for lymphoma: a systematic review and                    meta-analysis. Oncologist. 2010; 15: 750-759.","DOI":"10.1634\/theoncologist.2010-0054"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Shah                            NN,                                Ahn                            KW,                                Litovich                            C                    <i>et al.<\/i> Is autologous transplant in relapsed DLBCL patients                    achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021; 137:                    1416-1423.","DOI":"10.1182\/blood.2020007939"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Forrest                            DL,                                Nevill                            TJ,                                Naiman                            SC                    <i>et al.<\/i> Second malignancy following high-dose therapy and                    autologous stem cell transplantation: incidence and risk factor analysis. Bone                    Marrow Transplant. 2003; 32: 915-923.","DOI":"10.1038\/sj.bmt.1704243"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Brown                            JR,                                Yeckes                            H,                                Friedberg                            JW                    <i>et al.<\/i> Increasing incidence of late second malignancies after                    conditioning with cyclophosphamide and total-body irradiation and autologous                    bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005; 23:                    2208-2214.","DOI":"10.1200\/JCO.2005.05.158"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Darrington                            DL,                                Vose                            JM,                                Anderson                            JR                    <i>et al.<\/i> Incidence and characterization of secondary                    myelodysplastic syndrome and acute myelogenous leukemia following high-dose                    chemoradiotherapy and autologous stem-cell transplantation for lymphoid                    malignancies. J Clin Oncol. 1994; 12: 2527-2534.","DOI":"10.1200\/JCO.1994.12.12.2527"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Friedberg                            JW,                                Neuberg                            D,                                Stone                            RM                    <i>et al.<\/i> Outcome in patients with myelodysplastic syndrome after                    autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol.                    1999; 17: 3128-3135.","DOI":"10.1200\/JCO.1999.17.10.3128"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Metayer                            C,                                Curtis                            RE,                                Vose                            J                    <i>et al.<\/i> Myelodysplastic syndrome and acute myeloid leukemia                    after autotransplantation for lymphoma: a multicenter case-control study. Blood.                    2003; 101: 2015-2023.","DOI":"10.1182\/blood-2002-04-1261"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Vaxman                            I,                                Ram                            R,                                Gafter-Gvili                            A                    <i>et al.<\/i> Secondary malignancies following high dose therapy and                    autologous hematopoietic cell transplantation-systematic review and                    meta-analysis. Bone Marrow Transplant. 2015; 50: 706-714.","DOI":"10.1038\/bmt.2014.325"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Tarella                            C,                                Passera                            R,                                Magni                            M                    <i>et al.<\/i> Risk factors for the development of secondary malignancy                    after high-dose chemotherapy and autograft, with or without rituximab: a 20-year                    retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011; 29:                    814-824.","DOI":"10.1200\/JCO.2010.28.9777"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Hosing                            C,                                Munsell                            M,                                Yazji                            S                    <i>et al.<\/i> Risk of therapy-related myelodysplastic syndrome\/acute                    leukemia following high-dose therapy and autologous bone marrow transplantation                    for non-Hodgkin\u2019s lymphoma. Ann Oncol. 2002; 13: 450-459.","DOI":"10.1093\/annonc\/mdf109"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Neelapu                            SS,                                Locke                            FL,                                Bartlett                            NL                    <i>et al.<\/i> Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory                    Large B-Cell Lymphoma. N Engl J Med. 2017; 377: 2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Schuster                            SJ,                                Bishop                            MR,                                Tam                            CS                    <i>et al.<\/i> Tisagenlecleucel in Adult Relapsed or Refractory Diffuse                    Large B-Cell Lymphoma. N Engl J Med. 2019; 380: 45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Abramson                            JS,                                Palomba                            ML,                                Gordon                            LI                    <i>et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or                    refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless                    design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Locke                            FL,                                Miklos                            DB,                                Jacobson                            CA                    <i>et al.<\/i> Axicabtagene Ciloleucel as Second-Line Therapy for Large                    B-Cell Lymphoma. N Engl J Med. 2022; 386: 640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Kamdar                            M,                                Solomon                            SR,                                Arnason                            J                    <i>et al.<\/i> Lisocabtagene maraleucel versus standard of care with                    salvage chemotherapy followed by autologous stem cell transplantation as                    second-line treatment in patients with relapsed or refractory large B-cell                    lymphoma (TRANSFORM): results from an interim analysis of an open-label,                    randomised, phase 3 trial. Lancet. 2022; 399: 2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Bishop                            MR,                                Dickinson                            M,                                Purtill                            D                    <i>et al.<\/i> Second-Line Tisagenlecleucel or Standard Care in                    Aggressive B-Cell Lymphoma. N Engl J Med. 2022; 386: 629-639.","DOI":"10.1056\/NEJMoa2116596"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:11:19Z","timestamp":1688188279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23001","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23001"}}